Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P21108
UPID:
PRPS3_HUMAN
Alternative names:
Phosphoribosyl pyrophosphate synthase 1-like 1; Phosphoribosyl pyrophosphate synthase III
Alternative UPACC:
P21108; Q6P5P6
Background:
Ribose-phosphate pyrophosphokinase 3, also known as Phosphoribosyl pyrophosphate synthase 1-like 1 and Phosphoribosyl pyrophosphate synthase III, plays a pivotal role in nucleotide synthesis. It catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP), a critical precursor for the biosynthesis of nucleotides, essential for DNA and RNA production.
Therapeutic significance:
Understanding the role of Ribose-phosphate pyrophosphokinase 3 could open doors to potential therapeutic strategies. Its essential function in nucleotide synthesis makes it a potential target for developing treatments for diseases where nucleotide balance is disrupted.